BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kodera Y, Ito S, Fujiwara M, Mochizuki Y, Nakayama G, Ohashi N, Koike M, Yamamura Y, Nakao A. Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer: correlation with drug sensitivity against 5-fluorouracil. Cancer Lett. 2007;252:307-313. [PMID: 17303323 DOI: 10.1016/j.canlet.2007.01.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Hasegawa Y, Goto M, Hanai N, Ozawa T, Hirakawa H. Predictive biomarkers for combined chemotherapy with 5-fluorouracil and cisplatin in oro- and hypopharyngeal cancers. Mol Clin Oncol 2018;8:378-86. [PMID: 29399358 DOI: 10.3892/mco.2017.1521] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Choi IS, Lee HS, Lee KW, Kim H, Kim KH, Kim YJ, Kim JH, Kim WH, Lee JS. Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes. Med Oncol. 2011;28:991-998. [PMID: 20533001 DOI: 10.1007/s12032-010-9590-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
3 Tanigawa N, Yamaue H, Ohyama S, Sakuramoto S, Inada T, Kodera Y, Kitagawa Y, Omura K, Terashima M, Sakata Y, Nashimoto A, Yamaguchi T, Chin K, Nomura E, Lee SW, Takeuchi M, Fujii M, Nakajima T. Exploratory phase II trial in a multicenter setting to evaluate the clinical value of a chemosensitivity test in patients with gastric cancer (JACCRO-GC 04, Kubota memorial trial). Gastric Cancer 2016;19:350-60. [PMID: 26385385 DOI: 10.1007/s10120-015-0506-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
4 Tateishi Y, Tatemoto Y, Ohno S, Morishita K, Ueta E, Yamamoto T. Combined evaluation of dihydropyrimidine dehydrogenase and thymidine phosphorylate mRNA levels in tumor predicts the histopathological effect of 5-fluorouracil-based chemoradiotherapy. Cancer Letters 2009;274:187-93. [DOI: 10.1016/j.canlet.2008.09.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
5 Hua D, Huang ZH, Mao Y, Deng JZ. Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouraci-based adjuvant chemotherapy for gastric cancer. World J Gastroenterol 2007; 13(37): 5030-5034 [PMID: 17854149 DOI: 10.3748/wjg.v13.i37.5030] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
6 Kanda M, Kodera Y, Sakamoto J. Updated evidence on adjuvant treatments for gastric cancer. Expert Rev Gastroenterol Hepatol. 2015;9:1549-1560. [PMID: 26414453 DOI: 10.1586/17474124.2015.1094373] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
7 Scartozzi M, Maccaroni E, Giampieri R, Pistelli M, Bittoni A, Del Prete M, Berardi R, Cascinu S. 5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011;12:251-265. [PMID: 21332317 DOI: 10.2217/pgs.10.167] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
8 Scartozzi M, Bittoni A, Pistelli M, Galizia E, Berardi R, Giampieri R, Faloppi L, Cascinu S. Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives. Cancer Treat Rev 2009;35:451-62. [PMID: 19467788 DOI: 10.1016/j.ctrv.2009.04.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
9 Mori R, Futamura M, Tanahashi T, Tanaka Y, Matsuhashi N, Yamaguchi K, Yoshida K. 5FU resistance caused by reduced fluoro-deoxyuridine monophosphate and its reversal using deoxyuridine. Oncol Lett 2017;14:3162-8. [PMID: 28927061 DOI: 10.3892/ol.2017.6512] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
10 Wang X, Yan SK, Dai WX, Liu XR, Zhang WD, Wang JJ. A metabonomic approach to chemosensitivity prediction of cisplatin plus 5-fluorouracil in a human xenograft model of gastric cancer. Int J Cancer. 2010;127:2841-2850. [PMID: 21351263 DOI: 10.1002/ijc.25294] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
11 Griffith M, Mwenifumbo JC, Cheung PY, Paul JE, Pugh TJ, Tang MJ, Chittaranjan S, Morin RD, Asano JK, Ally AA. Novel mRNA isoforms and mutations of uridine monophosphate synthetase and 5-fluorouracil resistance in colorectal cancer. Pharmacogenomics J. 2013;13:148-158. [PMID: 22249354 DOI: 10.1038/tpj.2011.65] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
12 Shen X, Zhou C, Lian L, Li L, Li W, Tao M. Relationship Between the DPD and TS mRNA Expression and the Response to S-1-Based Chemotherapy and Prognosis in Patients with Advanced Gastric Cancer. Cell Biochem Biophys 2015;71:1653-61. [DOI: 10.1007/s12013-014-0387-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
13 Zhang C, Liu H, Ma B, Song Y, Gao P, Xu Y, Yu D, Wang Z. The Impact of the Expression Level of Intratumoral Dihydropyrimidine Dehydrogenase on Chemotherapy Sensitivity and Survival of Patients in Gastric Cancer: A Meta-Analysis. Dis Markers 2017;2017:9202676. [PMID: 28255193 DOI: 10.1155/2017/9202676] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
14 Takashima T, Hara F, Iwamoto T, Uemura Y, Ohsumi S, Yotsumoto D, Hozumi Y, Watanabe T, Saito T, Watanabe KI, Tsurutani J, Toyama T, Akabane H, Nishimura R, Taira N, Ohashi Y, Mukai H. A Correlation Analysis Between Metabolism-related Genes and Treatment Response to S-1 as First-line Chemotherapy for Metastatic Breast Cancer: The SELECT BC-EURECA Study. Clin Breast Cancer 2021;21:450-7. [PMID: 33685834 DOI: 10.1016/j.clbc.2021.01.018] [Reference Citation Analysis]
15 Suetsugu T, Mori R, Futamura M, Fukada M, Tanaka H, Yasufuku I, Sato Y, Iwata Y, Imai T, Imai H, Tanaka Y, Okumura N, Matsuhashi N, Takahashi T, Yoshida K. Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines. Oncol Rep 2021;45:27. [PMID: 33649846 DOI: 10.3892/or.2021.7978] [Reference Citation Analysis]
16 Huang L, Chen F, Chen Y, Yang X, Xu S, Ge S, Fu S, Chao T, Yu Q, Liao X, Hu G, Zhang P, Yuan X. Thymidine phosphorylase gene variant, platelet counts and survival in gastrointestinal cancer patients treated by fluoropyrimidines. Sci Rep 2014;4:5697. [PMID: 25027354 DOI: 10.1038/srep05697] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
17 Yoshikawa T, Aoyama T, Sakamaki K, Oshima T, Lin J, Zhang S, Sapari NS, Soong R, Tan I, Chan XB, Bottomley D, Hewitt LC, Arai T, Teh BT, Epstein D, Ogata T, Kameda Y, Miyagi Y, Tsuburaya A, Morita S, Grabsch HI, Tan P. Comprehensive biomarker analyses identifies HER2, EGFR, MET RNA expression and thymidylate synthase 5'UTR SNP as predictors of benefit from S-1 adjuvant chemotherapy in Japanese patients with stage II/III gastric cancer. J Cancer 2019;10:5130-8. [PMID: 31602266 DOI: 10.7150/jca.34741] [Reference Citation Analysis]
18 Tänzer M, Liebl M, Quante M. Molecular biomarkers in esophageal, gastric, and colorectal adenocarcinoma. Pharmacol Ther. 2013;140:133-147. [PMID: 23791941 DOI: 10.1016/j.pharmthera.2013.06.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
19 Shi WJ, Gao JB. Molecular mechanisms of chemoresistance in gastric cancer. World J Gastrointest Oncol 2016; 8(9): 673-681 [PMID: 27672425 DOI: 10.4251/wjgo.v8.i9.673] [Cited by in CrossRef: 77] [Cited by in F6Publishing: 69] [Article Influence: 15.4] [Reference Citation Analysis]
20 Nakamura A, Nakajima G, Okuyama R, Kuramochi H, Kondoh Y, Kanemura T, Takechi T, Yamamoto M, Hayashi K. Enhancement of 5-fluorouracil-induced cytotoxicity by leucovorin in 5-fluorouracil-resistant gastric cancer cells with upregulated expression of thymidylate synthase. Gastric Cancer 2014;17:188-95. [PMID: 23494117 DOI: 10.1007/s10120-013-0249-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
21 Mori R, Yoshida K, Futamura M, Suetsugu T, Shizu K, Tanahashi T, Tanaka Y, Matsuhashi N, Yamaguchi K. The inhibition of thymidine phosphorylase can reverse acquired 5FU-resistance in gastric cancer cells. Gastric Cancer 2019;22:497-505. [PMID: 30276573 DOI: 10.1007/s10120-018-0881-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]